Results 181 to 190 of about 4,565 (213)

Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination

Annals of Pharmacotherapy, 2018
Objective: To review the pharmacology, spectrum of activity, pharmacokinetics, pharmacodynamics, safety, efficacy, administration, and considerations for clinical use of meropenem/vaborbactam (M/V). Data Sources: A literature search using PubMed and clinicaltrials.gov (June 2013 to December 2017) was conducted using the search terms meropenem ...
Jonathan C, Cho, Monika T, Zmarlicka, Kristy M, Shaeer, Joe, Pardo   +3 more
openaire   +2 more sources

Imipenem–Relebactam and Meropenem–Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations

Drugs, 2017
Relebactam (formerly known as MK-7655) is a non-β-lactam, bicyclic diazabicyclooctane, β-lactamase inhibitor that is structurally related to avibactam, differing by the addition of a piperidine ring to the 2-position carbonyl group. Vaborbactam (formerly known as RPX7009) is a non-β-lactam, cyclic, boronic acid-based, β-lactamase inhibitor.
George G Zhanel, Courtney K Lawrence, Heather J Adam   +2 more
exaly   +3 more sources

An evaluation of meropenem/vaborbactam for the treatment of nosocomial pneumonia

Expert Opinion on Pharmacotherapy, 2020
Introduction: Nosocomial pneumonias are the second most common healthcare-associated infections (HCAIs), often associated with the presence of Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter species, and Enterobacter species.
Lauren M. Groft, Kimberly C. Claeys, Emily L. Heil   +2 more
openaire   +2 more sources

Meropenem–vaborbactam for adults with complicated urinary tract and other invasive infections

Expert Review of Anti-infective Therapy, 2018
Complicated urinary tract infections are increasingly caused by multidrug-resistant organisms. Carbapenem-resistant Enterobacteriaceae (CRE) constitute a rising threat among uropathogens with significant morbidity and mortality. Meropenem-vaborbactam is a novel carbapenem and cyclic boronic acid-based beta-lactamase inhibitor combination with potent ...
Owen R, Albin, Twisha S, Patel, Keith S, Kaye   +2 more
openaire   +6 more sources

A Brief Review of a New Antibiotic: Meropenem-vaborbactam

The Senior Care Pharmacist, 2019
Meropenem-vaborbactam is a newly approved antibiotic for complex urinary tract infections and to treat carbapenem-resistant Enterobacteriaceae infections. Its advantage over meropenem is the betalactamase inhibitor which slows bacterial resistance. This medication has been studied in numerous countries and has relatively few side effects.
openaire   +2 more sources

Meropenem/vaborbactam

Reactions Weekly, 2021
openaire   +2 more sources

Resistance to meropenem-vaborbactam in clinical isolates of Enterobacter roggenkampii without previous exposure to vaborbactam

Clinical Microbiology and Infection, 2022
Paula, Navarro-Carrera, Paloma, García-Clemente, Rosa, Gómez-Gil, Rubén, Cáceres-Sánchez, Iván, Bloise, Elias, Dahdouh, Francisco, Moreno-Ramos, Julio, García-Rodríguez, Jesús, Mingorance, Fernando, Lázaro-Perona   +9 more
openaire   +2 more sources

Meropenem – Vaborbactam

2022
Michelle C. Simpson, Eric G. Schaefer
openaire   +1 more source

Gentamicin/meropenem/vaborbactam

Reactions Weekly, 2021
openaire   +1 more source

A molecular analysis of meropenem–vaborbactam non-susceptible KPC-producing Klebsiella pneumoniae

Antimicrobial Agents and Chemotherapy
ABSTRACT We characterized the molecular determinants of meropenem–vaborbactam (MV) non-susceptibility among non-metallo-β-lactamase-producing KPC- Klebsiella pneumoniae (KPC- KP ).
Mohamad Yasmin, Steven H. Marshall, Liang Chen, Daniel D. Rhoads, Michael R. Jacobs, Laura J. Rojas, Federico Perez, Andrea M. Hujer, Kristine M. Hujer, David van Duin, Vance Fowler, Henry F. Chambers, Barry N. Kreiswirth, Robert A. Bonomo   +13 more
openaire   +2 more sources